Study of C1-inhibitor test for hereditary angioedema diagnosis
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years old or older.
- You or a close family member must have symptoms that suggest hereditary angioedema (HAE).
- Your swelling should not be pitted when pressed, should not have a rash or itching, and should last 1 to 5 days.
- If you are a family member, you must be a first- to fourth-degree relative of someone with known HAE.
- You must not already have a confirmed diagnosis of HAE type 1 or type 2.
- You must not have swelling with a rash or itching (which suggests a different cause).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study is looking at how hereditary angioedema (a rare cause of severe swelling) is diagnosed and managed in Egypt. It is an observational study, meaning you won't receive any study medicine—just regular medical care while researchers collect information.
This study tests a daily oral tablet called deucrictibant to see if it can prevent swelling attacks in people with hereditary angioedema (HAE). If you join, you will take the study drug for a longer period and track your symptoms in a diary.
This trial tests an oral medication called deucrictibant to prevent and treat swelling attacks in people with hereditary angioedema. It may help reduce the number and severity of attacks.
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
This study looks at whether people with hereditary angioedema (a rare condition causing sudden swelling) experience thoughts of suicide. The goal is to understand the emotional impact of living with this condition and find ways to support patients better.
Hear when a new Hereditary Angioedema (HAE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.